<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Vasc Health Risk Manag</journal-id><journal-id journal-id-type="publisher-id">Vascular Health and Risk Management</journal-id><journal-title-group><journal-title>Vascular Health and Risk Management</journal-title></journal-title-group><issn pub-type="ppub">1176-6344</issn><issn pub-type="epub">1178-2048</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19554089</article-id><article-id pub-id-type="pmc">2697583</article-id><article-id pub-id-type="publisher-id">vhrm-5-489</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Effects of allopurinol and vitamin E on renal function in patients with cardiac coronary artery bypass grafts</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Nouri-Majalan</surname><given-names>Nader</given-names></name><xref ref-type="aff" rid="af1-vhrm-5-489">1</xref></contrib><contrib contrib-type="author"><name><surname>Ardakani</surname><given-names>Ehsan Fotouhi</given-names></name><xref ref-type="aff" rid="af2-vhrm-5-489">2</xref></contrib><contrib contrib-type="author"><name><surname>Forouzannia</surname><given-names>Khalil</given-names></name><xref ref-type="aff" rid="af3-vhrm-5-489">3</xref></contrib><contrib contrib-type="author"><name><surname>Moshtaghian</surname><given-names>Hosein</given-names></name><xref ref-type="aff" rid="af4-vhrm-5-489">4</xref></contrib></contrib-group><aff id="af1-vhrm-5-489"><label>1</label>Department of Nephrology,</aff><aff id="af3-vhrm-5-489"><label>3</label>Department of Cardiovascular Surgery,</aff><aff id="af4-vhrm-5-489"><label>4</label>Department of Anesthesiology, Afshar Hospital, Shahid Sadoughi University of Medical Sciences, Yazd, Iran;</aff><aff id="af2-vhrm-5-489"><label>2</label>Ali bin Abu Taleb Medical College, Yazd Azad University, Yazd, Iran</aff><author-notes><corresp id="c1-vhrm-5-489">Correspondence: Nader Nouri-Majalan, Department of Nephrology, Shahid Sadoughi Medical University, Yazd, Iran, Tel +98 91 3152 6380, Fax +98 35 1822 4100, Email
<email>dr_nori_majelan@yahoo.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><!--Dove Press titles changed from ppub to collections in 2009.
								Fake ppub written to satisfy Coll Date Type=ppub--><pub-date pub-type="ppub"><year>2009</year></pub-date><pub-date pub-type="epub"><day>7</day><month>6</month><year>2009</year></pub-date><volume>5</volume><fpage>489</fpage><lpage>494</lpage><history><date date-type="received"><day>26</day><month>5</month><year>2009</year></date></history><permissions><copyright-statement>&#x000a9; 2009 Nouri-Majalan et al, publisher and licensee Dove Medical Press Ltd.</copyright-statement><license><license-p>This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Background:</title><p>Acute renal failure is a common complication of cardiac surgery, with oxidants found to play an important role in renal injury. We therefore assessed whether the supplemental antioxidant vitamin E and the inhibitor of xanthine oxidase allopurinol could prevent renal dysfunction after coronary artery bypass graft (CABG) surgery.</p></sec><sec><title>Methods:</title><p>Of 60 patients with glomerular filtration rate (GFR) &#x0003c; 60 mL/min scheduled to undergo CABG surgery, 30 were randomized to treatment with vitamin E and allopurinol for 3&#x02013;5 days before surgery and 30 to no treatment. Serum creatinine levels and potassium and creatinine clearances were measured preoperatively and daily until day 5 after surgery.</p></sec><sec><title>Results:</title><p>The patients consisted of 31 males and 29 females, with a mean age of 63 &#x000b1; 9 years. After surgery, there were no significant differences in mean serum creatinine (1.2 &#x000b1; 0.33 vs 1.2 &#x000b1; 0.4 mg/dL; p = 0.43) concentrations, or creatinine clearance (52 &#x000b1; 12.8 vs 52 &#x000b1; 12.8 mL/min; p = 0.9). The frequency of acute renal failure did not differ in treatment group compared with control (16% vs 13%; p = 0.5). Length of stay in the intensive care unit (ICU) was significantly longer in the control than in the treated group (3.9 &#x000b1; 1.5 vs 2.6 &#x000b1; 0.7 days; p &#x0003c; 0.001).</p></sec><sec><title>Conclusion:</title><p>Prophylactic treatment with vitamin E and allopurinol had no renoprotective effects in patients with pre-existing renal failure undergoing CABG surgery. Treatment with these agents, however, reduces the duration of ICU stay.</p></sec></abstract><kwd-group><kwd>antioxidants</kwd><kwd>coronary artery bypass</kwd><kwd>prevention and control</kwd><kwd>renal function</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Acute renal failure (ARF) is a common and dangerous complication of cardiac surgery, especially after surgery for cardiac coronary artery bypass graft (CABG),<xref rid="b1-vhrm-5-489" ref-type="bibr">1</xref> obstructive jaundice,<xref rid="b2-vhrm-5-489" ref-type="bibr">2</xref> and aortic aneurysm.<xref rid="b3-vhrm-5-489" ref-type="bibr">3</xref> ARF frequently arises because of decreased tissue perfusion, ischemia, adverse effects of free radicals,<xref rid="b4-vhrm-5-489" ref-type="bibr">4</xref> and blood vessel constriction stimulating the release of angiotensins such as endothelins.<xref rid="b5-vhrm-5-489" ref-type="bibr">5</xref> ARF following CABG has been found to increase mortality, morbidity, and intensive care unit (ICU) stay, with some patients requiring dialysis.<xref rid="b6-vhrm-5-489" ref-type="bibr">6</xref>,<xref rid="b7-vhrm-5-489" ref-type="bibr">7</xref> To date, no effective prophylaxis has been found to prevent ARF. Among the agents that have been tested are calcium channel blockers,<xref rid="b8-vhrm-5-489" ref-type="bibr">8</xref>,<xref rid="b9-vhrm-5-489" ref-type="bibr">9</xref> anti-endothelin,<xref rid="b10-vhrm-5-489" ref-type="bibr">10</xref>&#x02013;<xref rid="b12-vhrm-5-489" ref-type="bibr">12</xref> theophylline,<xref rid="b13-vhrm-5-489" ref-type="bibr">13</xref>,<xref rid="b14-vhrm-5-489" ref-type="bibr">14</xref> prostaglandin E1,<xref rid="b15-vhrm-5-489" ref-type="bibr">15</xref> low-dose dopamine,<xref rid="b16-vhrm-5-489" ref-type="bibr">16</xref>&#x02013;<xref rid="b19-vhrm-5-489" ref-type="bibr">19</xref> intercellular adhesion molecule 1 (ICAM 1),<xref rid="b20-vhrm-5-489" ref-type="bibr">20</xref>&#x02013;<xref rid="b22-vhrm-5-489" ref-type="bibr">22</xref> platelet-activating factor (PAF),<xref rid="b23-vhrm-5-489" ref-type="bibr">23</xref>,<xref rid="b24-vhrm-5-489" ref-type="bibr">24</xref> and alpha melanocyte-stimulating hormone (&#x003b1;MSH),<xref rid="b25-vhrm-5-489" ref-type="bibr">25</xref>,<xref rid="b26-vhrm-5-489" ref-type="bibr">26</xref> but results have not been satisfactory. As ischemia is involved in ARF after CABG, we assessed the effects of the supplemental antioxidant vitamin E and the inhibitor of xanthine oxidase allopurinol in the prophylaxis of ARF.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><p>The study involved patients with AFR undergoing CABG between March 2006 and March 2008. Inclusion criteria included age &#x0003e;18 years, glomerular filtration rate (GFR) &#x0003c; 60 mL/min, and no prior use of allopurinol or vitamin E. Exclusion criteria included nonelective emergency surgery, history of dialysis, allergy to vitamin E or allopurinol, and use of radio contrast media within three months prior to surgery. Patients were randomized to receive 100 units vitamin E four times per day and 100 mg allopurinol twice daily for three to five days prior to elective surgery, or to no treatment. None of patients were treated with these drugs before they were enrolled in the study. Patients in both groups were in the surgical ward and ICU of a cardiac super-specialization center and were treated under similar conditions. To prevent bias, the surgeons, nurses, and laboratory technicians were blinded to patient assignment. All patients received 1&#x02013;2 L of normal saline before surgery to prevent dehydration. The study protocol was approved by our Institutional Ethics Committee, and all patients provided informed consent.</p><p>We assessed baseline demographic characteristics, including age, gender, body mass index (BMI), blood pressure, and history of cigarette smoking, history of diabetes, and any previous myocardial infarction (MI). Serum creatinine and potassium concentrations were measured one day before surgery and daily for five days after surgery using standard laboratory methods. Creatinine clearance (CCr) was calculated using the Cockcroft&#x02013;Gault equation [CCr (mL/min) = (140 &#x02013; age) &#x000d7; lean body weight (kg)/Cr (mg/dL) &#x000d7; 72] for men, with multiplication by 0.85 required for women. ARF was defined as a fall in GFR by 25%. Other surgery-related parameters included the presence of arrhythmia during and after surgery, length of surgery, left ventricular ejection fraction (EF) before and after surgery, duration of time on-pump, use of a defibrillator, duration of aortic clamp (in minutes), episodes of hypotension (systolic blood pressure &#x0003c;90 mm Hg) during surgery, and need for dopamine and dobutamine infusion during and after operation. We also assessed the duration (in days) of ICU stay, mortality rate, and any adverse effects of allopurinol and Vitamin E.</p><sec sec-type="methods"><title>Statistical analysis</title><p>Data are expressed as means &#x000b1; standard deviations (SDs). Student&#x02019;s <italic>t</italic>-test and the Mann&#x02013;Whitney <italic>U</italic> test for unpaired data, or chi-square analysis, were used as appropriate to assess between-group differences. The SPSS 15 software program (SPSS Inc., Chicago, IL) was used for all analyses.</p></sec></sec><sec sec-type="results"><title>Results</title><p>During the study period, from March 13, 2006 until March 21, 2008, a total of 70 patients met our initial inclusion criteria. Of these, 10 were excluded, two because of a history of dialysis, three because of a history of injection with radio contrast media during the previous month, and five because of a history of allopurinol usage. Of the remaining 60 patients (31 males, 29 females), 30 were randomized to treatment with vitamin E and allopurinol and 30 to no treatment. The baseline demographic and clinical characteristics of the two groups were similar (Table <xref ref-type="table" rid="t1-vhrm-5-489">1</xref>).</p><p>After surgery, renal function, hemodynamic condition, ICU stay, and other parameters were compared between the two groups (Table <xref ref-type="table" rid="t2-vhrm-5-489">2</xref>). We found that GFR, serum creatinine concentration and the frequency of ARF did not differ significantly in the two groups. In contrast, length of stay in the ICU was significantly lower in the treatment group. For six months following surgery, no patient in either group died or required dialysis. Only one patient receiving allopurinol had skin lesions, on the last day of treatment.</p></sec><sec sec-type="discussion"><title>Discussion</title><p>We found that the combination of allopurinol and vitamin E did not have a significant effect after CABG on the renal function of patients with chronic renal failure. Among the possible causes of ARF after CABG are decreased tissue perfusion, ischemia, and free radical generation.<xref rid="b4-vhrm-5-489" ref-type="bibr">4</xref> To our knowledge, this study is the first to assess the effect of simultaneous treatment with allopurinol and vitamin E on kidney function in patients with pre-existing renal failure.</p><p>Allopurinol was selected as the choice of xanthine oxidase inhibitor because of the effects of this chemical on the ischemic process. For example, the blood concentrations of xanthine and hypoxanthine in CABG patients treated with either pump-on or pump-off procedures were shown to be significantly higher after than before surgery.<xref rid="b4-vhrm-5-489" ref-type="bibr">4</xref> Although these levels were higher in pump-on than in pump-off patients, the highest concentrations were observed in cases admitted to the ICU. In addition, Allopurinol inhibition of xanthine oxidase may have an impact on lesions of ischemia-reperfusion, a potential occurrence in CABG surgery, and a condition in which xanthine oxidase has clearly been implicated.<xref rid="b27-vhrm-5-489" ref-type="bibr">27</xref> The potential effect of decreasing urate levels of allopurinol could have the therapeutic effect. However, we did not measure urate level and it is a limitation of the study.</p><p>Although no prior studies have evaluated whether allopurinol might prevent ARF in humans, the xanthine oxidase inhibitor oxypurinol did not prevent decreased renal function in rats, which may be because of the effect of oxypurinol to prevent the proliferation of nephron tubular cells.<xref rid="b28-vhrm-5-489" ref-type="bibr">28</xref> Similarly, in our study, the lack of effect of allopurinol on renal function may be related to drug antiproliferative effects on tubular cells.<xref rid="b28-vhrm-5-489" ref-type="bibr">28</xref></p><p>Patients receiving allopurinol were also treated with the antioxidant vitamin E to determine if these two agents might show an additive effect in preventing renal dysfunction in patients with ischemia. In rats, the lipid-soluble antioxidant &#x003b1;-tocopherol was shown to reduce oxidative stress, thus decreasing chronic renal failure.<xref rid="b29-vhrm-5-489" ref-type="bibr">29</xref> Vitamin E may prevent acute decreases in renal function induced by ischemia, contrast media, or drugs.<xref rid="b30-vhrm-5-489" ref-type="bibr">30</xref> In pigs, the combination of vitamins E and C after cisplatin caused significant increases in renal total superoxide scavenger activity; this, in turn, strengthens the renal antioxidant system, eliminates oxidation reactions, and prevents cisplatin-induced kidney failure.<xref rid="b31-vhrm-5-489" ref-type="bibr">31</xref> Vitamin E has also been found to prevent acute tubular necrosis following glycerol administration in rats,<xref rid="b32-vhrm-5-489" ref-type="bibr">32</xref> and to prevent damage following renal ischemia.<xref rid="b33-vhrm-5-489" ref-type="bibr">33</xref> Roberts and colleagues<xref rid="b34-vhrm-5-489" ref-type="bibr">34</xref> have shown that a vitamin E treatment period of at least 16 weeks and 800 units/day was necessary for the significant increase in plasma concentrations of vitamin E. However we only used 3&#x02013;5 days and 400 units of vitamin E. Therefore, it may be that the lack of effects seen here is due to insufficient antioxidants.</p><p>We did not administer vitamin E and allopurinol after surgery due to their possible lack of effect on renal function. Therefore, we suggest postsurgical administration of these drugs in further studies.</p><p>Various clinical trials have assessed the ability of different interventions to prevent ARF after CABG. The antioxidant N-acetylcysteine was found to have no effect in preventing ARF in cardiac patients,<xref rid="b35-vhrm-5-489" ref-type="bibr">35</xref> or in reducing the rate of renal failure in patients undergoing heart and/or aortic surgery.<xref rid="b36-vhrm-5-489" ref-type="bibr">36</xref>&#x02013;<xref rid="b38-vhrm-5-489" ref-type="bibr">38</xref> The renal function of on-pump CABG patients was improved by leukodepletion, which prevented tubule destruction,<xref rid="b39-vhrm-5-489" ref-type="bibr">39</xref> and infusion of sodium nitroprusside resulted in improved renal function in cardiac patients.<xref rid="b40-vhrm-5-489" ref-type="bibr">40</xref> As hydration prior to surgery has been found to prevent renal damage,<xref rid="b41-vhrm-5-489" ref-type="bibr">41</xref> our patients were infused with 1&#x02013;2 L of normal saline to prevent confounding the effects of dehydration with those of allopurinol and vitamin E. Calcium channel blockers, such as diltiazem<xref rid="b42-vhrm-5-489" ref-type="bibr">42</xref> and verapamil,<xref rid="b43-vhrm-5-489" ref-type="bibr">43</xref> have been shown to increase urine output and to maintain tubular integrity after cardiac surgery, without significantly affecting the GFR. The selective dopamine receptor fenoldopam has been found to maintain creatinine clearance in the 0&#x02013;4 h and 4&#x02013;8 h intervals after CABG.<xref rid="b44-vhrm-5-489" ref-type="bibr">44</xref> Although dopamine has been used to prevent ARF, this drug has not been shown to have any effect.<xref rid="b19-vhrm-5-489" ref-type="bibr">19</xref>,<xref rid="b45-vhrm-5-489" ref-type="bibr">45</xref>,<xref rid="b46-vhrm-5-489" ref-type="bibr">46</xref> The ability of the &#x003b1;2-adrenergic receptor clonidine to prevent renal dysfunction in cardiac surgery patients may result from a reduction in the sympathetic nervous system response to CABG surgery.<xref rid="b47-vhrm-5-489" ref-type="bibr">47</xref> In a randomized study, simultaneous infusion of nifedipine and maintenance of the hemodynamic state resulted in preservation of GFR and creatinine clearance after cardiac surgery.<xref rid="b48-vhrm-5-489" ref-type="bibr">48</xref></p><p>We found that duration of ICU stay was significantly shorter in the treatment group than in the control patients. In addition to a renoprotective effect, fenoldopam reduced the duration of ICU stay compared with placebo,<xref rid="b49-vhrm-5-489" ref-type="bibr">49</xref> a finding similar to ours. Another randomized study showed that N-acetylcysteine had no effect on renal function, duration of mechanical ventilation, postsurgical mortality, or required dose of dopamine.<xref rid="b50-vhrm-5-489" ref-type="bibr">50</xref></p><p>Although the mechanism of action by which the combination of allopurinol and vitamin E reduces ICU stay is not known, the antioxidant and xanthine oxidase inhibition effects of these drugs may decrease the amount of free radicals after surgery. In a finding similar to our study, Bartels and colleagues<xref rid="b51-vhrm-5-489" ref-type="bibr">51</xref> showed that length of ICU stay was significantly shorter in the vitamin E treatment group than in the placebo group. Their explanation was that vitamin E could reduce the impact of ischemia and reperfusion injury in liver surgery. Goode and colleagues<xref rid="b52-vhrm-5-489" ref-type="bibr">52</xref> also found that decreased tocopherol (vitamin E) plasma concentrations in patients admitted to the ICU resulted in enhanced free radical activity.</p><p>Although the benefit effects of antioxidant and xanthine oxidase inhibitor were mentioned above, the adverse effects of radical scavenger on immune system have been reported. Remer and colleagues<xref rid="b53-vhrm-5-489" ref-type="bibr">53</xref> showed that nitric oxide played an important role in the control of brain infection with listeria and administration of radical scavenger resulted in rapid death of the treated animals. We did not compare the frequency of the infectious diseases in two groups. This subject should be considered in further studies.</p><p>We reported skin lesion in one patient receiving allopurinol. However, several other potentially severe adverse reactions associated with allopurinol administration such as Stevens&#x02013;Johnson syndrome and toxic epidermal necrolysis.<xref rid="b54-vhrm-5-489" ref-type="bibr">54</xref> On the other hand, large doses of vitamin E increase mortality.<xref rid="b55-vhrm-5-489" ref-type="bibr">55</xref> Therefore, the risk and benefit ratio of this treatment should be considered.</p></sec><sec><title>Conclusion</title><p>We found that the combination of vitamin E and allopurinol at the selected dose had no effect on renal function. Future studies, including patients with lower GFRs or higher creatinine levels, may show that antioxidants have significant effects on renal function. Allopurinol and vitamin E have a significant positive role in reducing the duration of ICU stay in CABG patients.</p></sec></body><back><fn-group><fn><p><bold>Disclosure</bold></p><p>The authors report no conflicts of interest in this work.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-vhrm-5-489"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thakar</surname><given-names>CV</given-names></name></person-group><article-title>A clinical score to predict acute renal failure after cardiac surgery</article-title><source>J Am Soc Nephrol</source><year>2005</year><volume>16</volume><issue>1</issue><fpage>162</fpage><lpage>168</lpage><pub-id pub-id-type="pmid">15563569</pub-id></mixed-citation></ref><ref id="b2-vhrm-5-489"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cahill</surname><given-names>CJ</given-names></name></person-group><article-title>Prevention of postoperative renal failure in patients with obstructive jaundice &#x02013; the role of bile salts</article-title><source>Br J Surg</source><year>1983</year><volume>70</volume><issue>10</issue><fpage>590</fpage><lpage>595</lpage><pub-id pub-id-type="pmid">6626919</pub-id></mixed-citation></ref><ref id="b3-vhrm-5-489"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gornick</surname><given-names>CC</given-names><suffix>Jr</suffix></name></person-group><article-title>Acute renal failure complicating aortic aneurysm surgery</article-title><source>Nephron</source><year>1983</year><volume>35</volume><issue>3</issue><fpage>145</fpage><lpage>157</lpage><pub-id pub-id-type="pmid">6633755</pub-id></mixed-citation></ref><ref id="b4-vhrm-5-489"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerritsen</surname><given-names>WB</given-names></name></person-group><article-title>Off-pump versus on-pump coronary artery bypass grafting: oxidative stress and renal function</article-title><source>Eur J Cardiothorac Surg</source><year>2001</year><volume>20</volume><issue>5</issue><fpage>923</fpage><lpage>929</lpage><pub-id pub-id-type="pmid">11675176</pub-id></mixed-citation></ref><ref id="b5-vhrm-5-489"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohan</surname><given-names>DE</given-names></name></person-group><article-title>Endothelins in the kidney: physiology and pathophysiology</article-title><source>Am J Kidney Dis</source><year>1993</year><volume>22</volume><issue>4</issue><fpage>493</fpage><lpage>510</lpage><pub-id pub-id-type="pmid">8213787</pub-id></mixed-citation></ref><ref id="b6-vhrm-5-489"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mangano</surname><given-names>CM</given-names></name></person-group><article-title>Renal dysfunction after myocardial revascularization: risk factors, adverse outcomes, and hospital resource utilization. The Multicenter Study of Perioperative Ischemia Research Group</article-title><source>Ann Intern Med</source><year>1998</year><volume>128</volume><issue>3</issue><fpage>194</fpage><lpage>203</lpage><pub-id pub-id-type="pmid">9454527</pub-id></mixed-citation></ref><ref id="b7-vhrm-5-489"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thakar</surname><given-names>CV</given-names></name></person-group><article-title>Influence of renal dysfunction on mortality after cardiac surgery: modifying effect of preoperative renal function</article-title><source>Kidney Int</source><year>2005</year><volume>67</volume><issue>3</issue><fpage>1112</fpage><lpage>1119</lpage><pub-id pub-id-type="pmid">15698452</pub-id></mixed-citation></ref><ref id="b8-vhrm-5-489"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conger</surname><given-names>J</given-names></name></person-group><article-title>Hemodynamic factors in acute renal failure</article-title><source>Adv Ren Replace Ther</source><year>1997</year><volume>4</volume><issue>2 Suppl 1</issue><fpage>25</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">9113238</pub-id></mixed-citation></ref><ref id="b9-vhrm-5-489"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verbeke</surname><given-names>M</given-names></name></person-group><article-title>Influence of ketanserin on experimental loss of renal blood flow autoregulation</article-title><source>Kidney Int Suppl</source><year>1998</year><volume>67</volume><fpage>S238</fpage><lpage>S241</lpage><pub-id pub-id-type="pmid">9736303</pub-id></mixed-citation></ref><ref id="b10-vhrm-5-489"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gellai</surname><given-names>M</given-names></name><etal/></person-group><article-title>Nonpeptide endothelin receptor antagonists. V: Prevention and reversal of acute renal failure in the rat by SB 209670</article-title><source>J Pharmacol Exp Ther</source><year>1995</year><volume>275</volume><issue>1</issue><fpage>200</fpage><lpage>206</lpage><pub-id pub-id-type="pmid">7562550</pub-id></mixed-citation></ref><ref id="b11-vhrm-5-489"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>L</given-names></name></person-group><article-title>Effect of an endothelin-receptor antagonist on ischemic acute renal failure</article-title><source>Am J Physiol</source><year>1994</year><volume>266</volume><fpage>F135</fpage><lpage>F138</lpage><pub-id pub-id-type="pmid">8304480</pub-id></mixed-citation></ref><ref id="b12-vhrm-5-489"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gellai</surname><given-names>M</given-names></name></person-group><article-title>Reversal of postischemic acute renal failure with a selective endothelinA receptor antagonist in the rat</article-title><source>J Clin Invest</source><year>1994</year><volume>93</volume><issue>2</issue><fpage>900</fpage><lpage>906</lpage><pub-id pub-id-type="pmid">8113422</pub-id></mixed-citation></ref><ref id="b13-vhrm-5-489"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erley</surname><given-names>CM</given-names></name></person-group><article-title>Does hydration prevent radiocontrast-induced acute renal failure?</article-title><source>Nephrol Dial Transplant</source><year>1999</year><volume>14</volume><issue>5</issue><fpage>1064</fpage><lpage>1066</lpage><pub-id pub-id-type="pmid">10344335</pub-id></mixed-citation></ref><ref id="b14-vhrm-5-489"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erley</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Prevention of radiocontrast-media-induced nephropathy in patients with pre-existing renal insufficiency by hydration in combination with the adenosine antagonist theophylline</article-title><source>Nephrol Dial Transplant</source><year>1999</year><volume>14</volume><issue>5</issue><fpage>1146</fpage><lpage>1149</lpage><pub-id pub-id-type="pmid">10344353</pub-id></mixed-citation></ref><ref id="b15-vhrm-5-489"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koch</surname><given-names>JA</given-names></name></person-group><article-title>Prostaglandin E1: a new agent for the prevention of renal dysfunction in high risk patients caused by radiocontrast media? PGE1 Study Group</article-title><source>Nephrol Dial Transplant</source><year>2000</year><volume>15</volume><issue>1</issue><fpage>43</fpage><lpage>49</lpage></mixed-citation></ref><ref id="b16-vhrm-5-489"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>MR</given-names></name></person-group><article-title>Dopamine and the kidney: ten years on</article-title><source>Clin Sci (Lond)</source><year>1993</year><volume>84</volume><issue>4</issue><fpage>357</fpage><lpage>375</lpage><pub-id pub-id-type="pmid">8482041</pub-id></mixed-citation></ref><ref id="b17-vhrm-5-489"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aperia</surname><given-names>A</given-names></name></person-group><article-title>Dopamine action and metabolism in the kidney</article-title><source>Curr Opin Nephrol Hypertens</source><year>1994</year><volume>3</volume><issue>1</issue><fpage>39</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">7850410</pub-id></mixed-citation></ref><ref id="b18-vhrm-5-489"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Denton</surname><given-names>MD</given-names></name></person-group><article-title>&#x0201c;Renal-dose&#x0201d; dopamine for the treatment of acute renal failure: scientific rationale, experimental studies and clinical trials</article-title><source>Kidney Int</source><year>1996</year><volume>50</volume><issue>1</issue><fpage>4</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">8807566</pub-id></mixed-citation></ref><ref id="b19-vhrm-5-489"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lassnigg</surname><given-names>A</given-names></name></person-group><article-title>Lack of renoprotective effects of dopamine and furosemide during cardiac surgery</article-title><source>J Am Soc Nephrol</source><year>2000</year><volume>11</volume><issue>1</issue><fpage>97</fpage><lpage>104</lpage><pub-id pub-id-type="pmid">10616845</pub-id></mixed-citation></ref><ref id="b20-vhrm-5-489"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rabb</surname><given-names>H</given-names></name></person-group><article-title>Leucocyte adhesion molecules in ischaemic renal injury: kidney specific paradigms?</article-title><source>Clin Exp Pharmacol Physiol</source><year>1998</year><volume>25</volume><issue>3&#x02013;4</issue><fpage>286</fpage><lpage>291</lpage><pub-id pub-id-type="pmid">9590585</pub-id></mixed-citation></ref><ref id="b21-vhrm-5-489"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Greef</surname><given-names>KE</given-names></name><etal/></person-group><article-title>Neutrophils and acute ischemia-reperfusion injury</article-title><source>J Nephrol</source><year>1998</year><volume>11</volume><issue>3</issue><fpage>110</fpage><lpage>122</lpage><pub-id pub-id-type="pmid">9650119</pub-id></mixed-citation></ref><ref id="b22-vhrm-5-489"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonventre</surname><given-names>JV</given-names></name></person-group><article-title>Adhesion molecules and acute renal failure</article-title><source>Adv Nephrol Necker Hosp</source><year>1996</year><volume>25</volume><fpage>159</fpage><lpage>176</lpage><pub-id pub-id-type="pmid">8717626</pub-id></mixed-citation></ref><ref id="b23-vhrm-5-489"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>L&#x000f3;pez-Novoa</surname><given-names>JM</given-names></name></person-group><article-title>Potential role of platelet activating factor in acute renal failure</article-title><source>Kidney Int</source><year>1999</year><volume>55</volume><issue>5</issue><fpage>1672</fpage><lpage>1682</lpage><pub-id pub-id-type="pmid">10231429</pub-id></mixed-citation></ref><ref id="b24-vhrm-5-489"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grino</surname><given-names>JM</given-names></name></person-group><article-title>BN 52021: a platelet activating factor antagonist for preventing post-transplant renal failure. A double-blind, randomized study. The BN 52021 Study Group in Renal Transplantation</article-title><source>Ann Intern Med</source><year>1994</year><volume>121</volume><issue>5</issue><fpage>345</fpage><lpage>347</lpage><pub-id pub-id-type="pmid">8042824</pub-id></mixed-citation></ref><ref id="b25-vhrm-5-489"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohda</surname><given-names>Y</given-names></name></person-group><article-title>Alpha-Melanocyte-stimulating hormone and acute renal failure</article-title><source>Curr Opin Nephrol Hypertens</source><year>1998</year><volume>7</volume><issue>4</issue><fpage>413</fpage><lpage>417</lpage><pub-id pub-id-type="pmid">9690041</pub-id></mixed-citation></ref><ref id="b26-vhrm-5-489"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiao</surname><given-names>H</given-names></name></person-group><article-title>Alpha-melanocyte-stimulating hormone protects against renal injury after ischemia in mice and rats</article-title><source>J Clin Invest</source><year>1997</year><volume>99</volume><issue>6</issue><fpage>1165</fpage><lpage>1172</lpage><pub-id pub-id-type="pmid">9077523</pub-id></mixed-citation></ref><ref id="b27-vhrm-5-489"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coghlan</surname><given-names>JG</given-names></name><etal/></person-group><article-title>Allopurinol pretreatment improves postoperative recovery and reduces lipid peroxidation in patients undergoing coronary artery bypass grafting</article-title><source>J Thorac Cardiovasc Surg</source><year>1994</year><volume>107</volume><issue>1</issue><fpage>248</fpage><lpage>256</lpage><pub-id pub-id-type="pmid">8283893</pub-id></mixed-citation></ref><ref id="b28-vhrm-5-489"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zager</surname><given-names>RA</given-names></name></person-group><article-title>An evaluation of antioxidant effects on recovery from postischemic acute renal failure</article-title><source>J Am Soc Nephrol</source><year>1994</year><volume>4</volume><issue>8</issue><fpage>1588</fpage><lpage>1597</lpage><pub-id pub-id-type="pmid">7912960</pub-id></mixed-citation></ref><ref id="b29-vhrm-5-489"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forde</surname><given-names>P</given-names></name></person-group><article-title>Prevention of hypertension and renal dysfunction in Dahl rats by alpha-tocopherol</article-title><source>J Cardiovasc Pharmacol</source><year>2003</year><volume>42</volume><issue>1</issue><fpage>82</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">12827031</pub-id></mixed-citation></ref><ref id="b30-vhrm-5-489"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tepel</surname><given-names>M</given-names></name></person-group><article-title>Antioxidant therapy in vascular and renal diseases</article-title><source>Med Klin (Munich)</source><year>2002</year><volume>97</volume><issue>3</issue><fpage>144</fpage><lpage>151</lpage><pub-id pub-id-type="pmid">11957789</pub-id></mixed-citation></ref><ref id="b31-vhrm-5-489"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durak</surname><given-names>I</given-names></name></person-group><article-title>Cisplatin induces acute renal failure by impairing antioxidant system in guinea pigs: effects of antioxidant supplementation on the cisplatin nephrotoxicity</article-title><source>Drug Chem Toxicol</source><year>2002</year><volume>25</volume><issue>1</issue><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">11850966</pub-id></mixed-citation></ref><ref id="b32-vhrm-5-489"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akpolat</surname><given-names>T</given-names></name><etal/></person-group><article-title>Effect of vitamin E and pentoxifylline on glycerol-induced acute renal failure</article-title><source>Nephron</source><year>2000</year><volume>84</volume><issue>3</issue><fpage>243</fpage><lpage>247</lpage><pub-id pub-id-type="pmid">10720895</pub-id></mixed-citation></ref><ref id="b33-vhrm-5-489"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zurovsky</surname><given-names>Y</given-names></name></person-group><article-title>Unilateral renal ischemia reperfusion in the rat: effect of blood volume trapped in the kidney, sucrose infusion, and antioxidant treatments</article-title><source>Exp Toxicol Pathol</source><year>1995</year><volume>47</volume><issue>6</issue><fpage>471</fpage><lpage>478</lpage><pub-id pub-id-type="pmid">8871086</pub-id></mixed-citation></ref><ref id="b34-vhrm-5-489"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>LJ</given-names><suffix>2nd</suffix></name><etal/></person-group><article-title>The relationship between dose of vitamin E and suppression of oxidative stress in humans</article-title><source>Free Radic Biol Med</source><year>2007</year><volume>43</volume><issue>10</issue><fpage>1388</fpage><lpage>1393</lpage><pub-id pub-id-type="pmid">17936185</pub-id></mixed-citation></ref><ref id="b35-vhrm-5-489"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ristikankare</surname><given-names>A</given-names></name><etal/></person-group><article-title>Lack of renoprotective effect of i.v. N-acetylcysteine in patients with chronic renal failure undergoing cardiac surgery</article-title><source>Br J Anaesth</source><year>2006</year><volume>97</volume><issue>5</issue><fpage>611</fpage><lpage>616</lpage><pub-id pub-id-type="pmid">16914459</pub-id></mixed-citation></ref><ref id="b36-vhrm-5-489"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haase</surname><given-names>M</given-names></name><etal/></person-group><article-title>Phase II, randomized, controlled trial of high-dose N-acetylcysteine in high-risk cardiac surgery patients</article-title><source>Crit Care Med</source><year>2007</year><volume>35</volume><issue>5</issue><fpage>1324</fpage><lpage>1331</lpage><pub-id pub-id-type="pmid">17414730</pub-id></mixed-citation></ref><ref id="b37-vhrm-5-489"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komisarof</surname><given-names>JA</given-names></name></person-group><article-title>N-acetylcysteine for patients with prolonged hypotension as prophylaxis for acute renal failure (NEPHRON)</article-title><source>Crit Care Med</source><year>2007</year><volume>35</volume><issue>2</issue><fpage>435</fpage><lpage>441</lpage><pub-id pub-id-type="pmid">17205018</pub-id></mixed-citation></ref><ref id="b38-vhrm-5-489"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hynninen</surname><given-names>MS</given-names></name><etal/></person-group><article-title>N-acetylcysteine for the prevention of kidney injury in abdominal aortic surgery: a randomized, double-blind, placebo-controlled trial</article-title><source>Anesth Analg</source><year>2006</year><volume>102</volume><issue>6</issue><fpage>1638</fpage><lpage>1645</lpage><pub-id pub-id-type="pmid">16717300</pub-id></mixed-citation></ref><ref id="b39-vhrm-5-489"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolcal</surname><given-names>C</given-names></name><etal/></person-group><article-title>Leukodepletion improves renal function in patients with renal dysfunction undergoing on-pump coronary bypass surgery: a prospective randomized study</article-title><source>Thorac Cardiovasc Surg</source><year>2007</year><volume>55</volume><issue>2</issue><fpage>89</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">17377860</pub-id></mixed-citation></ref><ref id="b40-vhrm-5-489"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaya</surname><given-names>K</given-names></name><etal/></person-group><article-title>The effect of sodium nitroprusside infusion on renal function during reperfusion period in patients undergoing coronary artery bypass grafting: a prospective randomized clinical trial</article-title><source>Eur J Cardiothorac Surg</source><year>2007</year><volume>31</volume><issue>2</issue><fpage>290</fpage><lpage>297</lpage><pub-id pub-id-type="pmid">17174559</pub-id></mixed-citation></ref><ref id="b41-vhrm-5-489"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marathias</surname><given-names>KP</given-names></name><etal/></person-group><article-title>Preoperative intravenous hydration confers renoprotection in patients with chronic kidney disease undergoing cardiac surgery</article-title><source>Artif Organs</source><year>2006</year><volume>30</volume><issue>8</issue><fpage>615</fpage><lpage>621</lpage><pub-id pub-id-type="pmid">16911315</pub-id></mixed-citation></ref><ref id="b42-vhrm-5-489"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piper</surname><given-names>SN</given-names></name><etal/></person-group><article-title>Diltiazem may preserve renal tubular integrity after cardiac surgery</article-title><source>Can J Anaesth</source><year>2003</year><volume>50</volume><issue>3</issue><fpage>285</fpage><lpage>292</lpage><pub-id pub-id-type="pmid">12620953</pub-id></mixed-citation></ref><ref id="b43-vhrm-5-489"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tataranni</surname><given-names>G</given-names></name><etal/></person-group><article-title>Beneficial effects of verapamil in renal-risk surgical patients</article-title><source>Ren Fail</source><year>1994</year><volume>16</volume><issue>3</issue><fpage>383</fpage><lpage>390</lpage><pub-id pub-id-type="pmid">8059021</pub-id></mixed-citation></ref><ref id="b44-vhrm-5-489"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halpenny</surname><given-names>M</given-names></name></person-group><article-title>Fenoldopam: renal and splanchnic effects in patients undergoing coronary artery bypass grafting</article-title><source>Anaesthesia</source><year>2001</year><volume>56</volume><issue>10</issue><fpage>953</fpage><lpage>960</lpage><pub-id pub-id-type="pmid">11576097</pub-id></mixed-citation></ref><ref id="b45-vhrm-5-489"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>AT</given-names></name></person-group><article-title>The effect of &#x02018;renal-dose&#x02019; dopamine on renal tubular function following cardiac surgery: assessed by measuring retinol binding protein (RBP)</article-title><source>Eur J Cardiothorac Surg</source><year>1999</year><volume>15</volume><issue>5</issue><fpage>717</fpage><lpage>722</lpage><pub-id pub-id-type="pmid">10386423</pub-id></mixed-citation></ref><ref id="b46-vhrm-5-489"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baldwin</surname><given-names>L</given-names></name></person-group><article-title>Effect of postoperative low-dose dopamine on renal function after elective major vascular surgery</article-title><source>Ann Intern Med</source><year>1994</year><volume>120</volume><issue>9</issue><fpage>744</fpage><lpage>747</lpage><pub-id pub-id-type="pmid">8147547</pub-id></mixed-citation></ref><ref id="b47-vhrm-5-489"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kulka</surname><given-names>PJ</given-names></name></person-group><article-title>Preoperative alpha2-adrenergic receptor agonists prevent the deterioration of renal function after cardiac surgery: results of a randomized, controlled trial</article-title><source>Crit Care Med</source><year>1996</year><volume>24</volume><issue>6</issue><fpage>947</fpage><lpage>952</lpage><pub-id pub-id-type="pmid">8681596</pub-id></mixed-citation></ref><ref id="b48-vhrm-5-489"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertolissi</surname><given-names>M</given-names></name></person-group><article-title>Effects on renal function of a continuous infusion of nifedipine during cardiopulmonary bypass</article-title><source>J Cardiothorac Vasc Anesth</source><year>1996</year><volume>10</volume><issue>2</issue><fpage>238</fpage><lpage>242</lpage><pub-id pub-id-type="pmid">8850405</pub-id></mixed-citation></ref><ref id="b49-vhrm-5-489"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caimmi</surname><given-names>PP</given-names></name><etal/></person-group><article-title>Fenoldopam for renal protection in patients undergoing cardiopulmonary bypass</article-title><source>J Cardiothorac Vasc Anesth</source><year>2003</year><volume>17</volume><issue>4</issue><fpage>491</fpage><lpage>494</lpage><pub-id pub-id-type="pmid">12968238</pub-id></mixed-citation></ref><ref id="b50-vhrm-5-489"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burns</surname><given-names>KE</given-names></name><etal/></person-group><article-title>Perioperative N-acetylcysteine to prevent renal dysfunction in high-risk patients undergoing cabg surgery: a randomized controlled trial</article-title><source>JAMA</source><year>2005</year><volume>294</volume><issue>3</issue><fpage>342</fpage><lpage>350</lpage><pub-id pub-id-type="pmid">16030279</pub-id></mixed-citation></ref><ref id="b51-vhrm-5-489"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartels</surname><given-names>M</given-names></name></person-group><article-title>Pilot study on the effect of parenteral vitamin E on ischemia and reperfusion induced liver injury: a double blind, randomized, placebo-controlled trial</article-title><source>Clin Nutr</source><year>2004</year><volume>23</volume><issue>6</issue><fpage>1360</fpage><lpage>1370</lpage><pub-id pub-id-type="pmid">15556258</pub-id></mixed-citation></ref><ref id="b52-vhrm-5-489"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goode</surname><given-names>HF</given-names></name></person-group><article-title>Decreased antioxidant status and increased lipid peroxidation in patients with septic shock and secondary organ dysfunction</article-title><source>Crit Care Med</source><year>1995</year><volume>23</volume><issue>4</issue><fpage>646</fpage><lpage>651</lpage><pub-id pub-id-type="pmid">7712754</pub-id></mixed-citation></ref><ref id="b53-vhrm-5-489"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Remer</surname><given-names>KA</given-names></name></person-group><article-title>The role of nitric oxide in Listeria encephalitis of ruminants and in rats intracisternally infected with Listeria monocytogenes</article-title><source>Berl Munch Tierarztl Wochenschr</source><year>2002</year><volume>115</volume><fpage>7</fpage><lpage>8</lpage><fpage>259</fpage><lpage>266</lpage></mixed-citation></ref><ref id="b54-vhrm-5-489"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>HY</given-names></name></person-group><article-title>Allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis</article-title><source>J Am Acad Dermatol</source><year>2008</year><volume>59</volume><issue>2</issue><fpage>352</fpage><lpage>353</lpage><pub-id pub-id-type="pmid">18638633</pub-id></mixed-citation></ref><ref id="b55-vhrm-5-489"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lundberg</surname><given-names>GD</given-names></name></person-group><article-title>Antioxidant supplements found not to improve human survival</article-title><source>Medscape J Med</source><year>2008</year><volume>10</volume><issue>9</issue><fpage>222</fpage><pub-id pub-id-type="pmid">19008983</pub-id></mixed-citation></ref></ref-list></back><floats-group><table-wrap id="t1-vhrm-5-489" position="float"><label>Table 1</label><caption><p>Baseline clinical and demographic characteristics of patients in the control and treatment groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>Variable</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Treatment group</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Control group</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>p value</bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Age</td><td valign="top" align="left" rowspan="1" colspan="1">65 &#x000b1; 9.5 years</td><td valign="top" align="left" rowspan="1" colspan="1">61 &#x000b1; 7.90 years</td><td valign="top" align="left" rowspan="1" colspan="1">0.103</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Sex (M/F)</td><td valign="top" align="left" rowspan="1" colspan="1">17/13</td><td valign="top" align="left" rowspan="1" colspan="1">14/16</td><td valign="top" align="left" rowspan="1" colspan="1">0.4</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BMI</td><td valign="top" align="left" rowspan="1" colspan="1">24.4 &#x000b1; 3.22</td><td valign="top" align="left" rowspan="1" colspan="1">24.1 &#x000b1; 2.53</td><td valign="top" align="left" rowspan="1" colspan="1">0.77</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">DM (no.)</td><td valign="top" align="left" rowspan="1" colspan="1">11</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">0.71</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">HTN (no.)</td><td valign="top" align="left" rowspan="1" colspan="1">14</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">0.59</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">History of MI (no.)</td><td valign="top" align="left" rowspan="1" colspan="1">17</td><td valign="top" align="left" rowspan="1" colspan="1">11</td><td valign="top" align="left" rowspan="1" colspan="1">0.108</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Smoking (no.)</td><td valign="top" align="left" rowspan="1" colspan="1">11</td><td valign="top" align="left" rowspan="1" colspan="1">4</td><td valign="top" align="left" rowspan="1" colspan="1">0.016</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Duration of operation (h)</td><td valign="top" align="left" rowspan="1" colspan="1">3.6 &#x000b1; 0.56</td><td valign="top" align="left" rowspan="1" colspan="1">3.2 &#x000b1; 0.83</td><td valign="top" align="left" rowspan="1" colspan="1">0.169</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Duration of aortic clamp (min)</td><td valign="top" align="left" rowspan="1" colspan="1">32.5 &#x000b1; 13.33</td><td valign="top" align="left" rowspan="1" colspan="1">24.3 &#x000b1; 9.76</td><td valign="top" align="left" rowspan="1" colspan="1">0.185</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Pump on (no.)</td><td valign="top" align="left" rowspan="1" colspan="1">25</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">0.31</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Preoperation EF</td><td valign="top" align="left" rowspan="1" colspan="1">44.7 &#x000b1; 12.29</td><td valign="top" align="left" rowspan="1" colspan="1">49.4 &#x000b1; 12.6</td><td valign="top" align="left" rowspan="1" colspan="1">0.354</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Preoperation serum Cr (mg/dL)</td><td valign="top" align="left" rowspan="1" colspan="1">1.3 &#x000b1; 0.45</td><td valign="top" align="left" rowspan="1" colspan="1">1.3 &#x000b1; 0.53</td><td valign="top" align="left" rowspan="1" colspan="1">0.918</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Preoperation serum potassium (meq/L)</td><td valign="top" align="left" rowspan="1" colspan="1">4.6 &#x000b1; 0.48</td><td valign="top" align="left" rowspan="1" colspan="1">4.2 &#x000b1; 0.66</td><td valign="top" align="left" rowspan="1" colspan="1">0.019</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Preoperation CCr (mL/min)</td><td valign="top" align="left" rowspan="1" colspan="1">48 &#x000b1; 10</td><td valign="top" align="left" rowspan="1" colspan="1">50 &#x000b1; 10.3</td><td valign="top" align="left" rowspan="1" colspan="1">0.412</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Urine volume (mL)</td><td valign="top" align="left" rowspan="1" colspan="1">1689.1 &#x000b1; 921.20</td><td valign="top" align="left" rowspan="1" colspan="1">1530.0 &#x000b1; 554.43</td><td valign="top" align="left" rowspan="1" colspan="1">0.518</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-vhrm-5-489"><p><bold>Notes:</bold> <sup>a</sup>Normal distribution of continuous variables was proven by Kolmogorov&#x02013;smirnov;</p></fn><fn id="tfn2-vhrm-5-489"><label><sup>b</sup></label><p>By a Bonferroni correction, a p value &#x0003c; 0.00333 was considered significant.</p></fn><fn id="tfn3-vhrm-5-489"><p><bold>Abbreviations:</bold> BMI, body mass index; DM, diabetes mellitus; HTN, hypertension; MI, myocardial infarction; EF, ejection fraction; Cr, creatinine; CCr, creatinine clearance; h, hour; min, minute.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-vhrm-5-489" position="float"><label>Table 2</label><caption><p>Clinical and paraclinical state of patients during and after surgery in the treatment and control groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>Variable</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Treatment group</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Control group</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>P value</bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Postoperation serum potassium (meq/L)</td><td valign="top" align="left" rowspan="1" colspan="1">4.4 &#x000b1; 0.30</td><td valign="top" align="left" rowspan="1" colspan="1">4.3 &#x000b1; 0.36</td><td valign="top" align="left" rowspan="1" colspan="1">0.784</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Postoperation serum creatinine (mg/dL)</td><td valign="top" align="left" rowspan="1" colspan="1">1.2 &#x000b1; 0.33</td><td valign="top" align="left" rowspan="1" colspan="1">1.2 &#x000b1; 0.40</td><td valign="top" align="left" rowspan="1" colspan="1">0.435</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Postoperation CCr (mL/min)</td><td valign="top" align="left" rowspan="1" colspan="1">52.5 &#x000b1; 12.84</td><td valign="top" align="left" rowspan="1" colspan="1">52.3 &#x000b1; 12.89</td><td valign="top" align="left" rowspan="1" colspan="1">0.952</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Postoperation ARF (no.)</td><td valign="top" align="left" rowspan="1" colspan="1">5</td><td valign="top" align="left" rowspan="1" colspan="1">4</td><td valign="top" align="left" rowspan="1" colspan="1">0.5</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Postoperation EF</td><td valign="top" align="left" rowspan="1" colspan="1">44 &#x000b1; 10.9</td><td valign="top" align="left" rowspan="1" colspan="1">45 &#x000b1; 10.4</td><td valign="top" align="left" rowspan="1" colspan="1">0.74</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Received dopamine infusion (no.)</td><td valign="top" align="left" rowspan="1" colspan="1">8</td><td valign="top" align="left" rowspan="1" colspan="1">5</td><td valign="top" align="left" rowspan="1" colspan="1">0.65</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Hypotension (systolic BP &#x02264;90 mm Hg) (no.)</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">6</td><td valign="top" align="left" rowspan="1" colspan="1">0.034</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Arrhythmia (no.)</td><td valign="top" align="left" rowspan="1" colspan="1">12</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">0.56</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ICU stay (day)</td><td valign="top" align="left" rowspan="1" colspan="1">2.6 &#x000b1; 0.75</td><td valign="top" align="left" rowspan="1" colspan="1">3.9 &#x000b1; 1.54</td><td valign="top" align="left" rowspan="1" colspan="1">0.000</td></tr></tbody></table><table-wrap-foot><fn id="tfn4-vhrm-5-489"><p><bold>Notes:</bold> <sup>a</sup>Normal distribution of continuous variables was proven by Kolmogorov&#x02013;smirnov;</p></fn><fn id="tfn5-vhrm-5-489"><label><sup>b</sup></label><p>By a Bonferroni correction, a p value &#x0003c; 0.00555 was considered significant;</p></fn><fn id="tfn6-vhrm-5-489"><label><sup>c</sup></label><p>During surgery;</p></fn><fn id="tfn7-vhrm-5-489"><label><sup>d</sup></label><p>A parametrical test (student&#x02019;s <italic>t</italic>-test) was performed. However, a nonparametrical test (Mann&#x02013;Whitney <italic>U</italic> test) was also performed and a P value of 0.004 was obtained.</p></fn><fn id="tfn8-vhrm-5-489"><p><bold>Abbreviations:</bold> EF, ejection fraction; CCr, creatinine clearance; min, minute; ARF, acute renal failure; ICU, intensive care unit.</p></fn></table-wrap-foot></table-wrap></floats-group></article>